Document:

kblb_ex1015.htm

Exhibit 10.15

 

INTELLECTUAL PROPERTY/COLLABORATIVE RESEARCH AGREEMENT

between

Kraig Biocraft Laboratories, Inc.

(SPONSOR)

and

The University of Notre Dame du Lac

(NOTRE DAME)

1.           Scope of Work

SPONSOR grants to NOTRE DAME and NOTRE DAME accepts support for basic research investigations under the direction of Dr. Malcolm Fraser at College of Science in the department of Biological Science as described in the attached Statement of Work (Attachment A). NOTRE DAME undertakes this research in furtherance of its goal of seeking new knowledge.

2.           Compensation

In consideration of NOTRE DAME's exerting its good faith efforts to carry out the research described in Attachment A (Research Plan), SPONSOR will pay NOTRE DAME the amounts specified in, and in the manner provided by, Attachment B (Compensation).

3.           Period of Performance

Research under this Agreement will be performed during the period September 30, 2015 through March 31, 2016.

4.           Technical Representatives

SPONSOR's technical representative shall be Kim Thompson or such other representative as SPONSOR may subsequently designate in writing. NOTRE DAME's Principal Investigator shall be Dr. Malcolm Fraser who shall be responsible for the direction and conduct of the Research.

5.           Consultation with SPONSOR's Representatives

During the period of this Agreement, SPONSOR's Technical/Scientific Representative and other representatives may have reasonable access to consult informally with NOTRE DAME's Principal Investigator regarding the Research both personally and by telephone. Access to work carried on in NOTRE DAME Laboratories in the course of the Research shall be entirely under the control of NOTRE DAME personnel; SPONSOR's representatives shall be permitted to visit such laboratories only during usual hours of operation as is mutually agreeable.

6.           Technical Reports

The Principal Investigator shall make up to four (4) oral reports each year if requested by SPONSOR's Technical Representative. Within sixty (60) days after the expiration of this Agreement, the Principal Investigator shall submit a comprehensive final report to SPONSOR.

 

  

  

  

 

7.           Publicity

Neither party shall use the name of the other in any form of advertising or promotion without the prior written approval of the other. The parties may, however, acknowledge SPONSOR's support for, and the nature of, the investigations being pursued under this Agreement. In any such statement, the relationship of the parties shall be accurately and appropriately described.

8.           Publication

NOTRE DAME has the right to publish and otherwise publicly disclose information it has gained in the course of the Research. In order to permit SPONSOR an opportunity to determine if patentable inventions are disclosed, the Principal Investigator will provide Sponsor with copies of articles written by project personnel reporting on the Research prior to or coincidental with submission for publication. NOTRE DAME and SPONSOR shall inform the Principal Investigator of the effect on patent rights of the disclosure of patentable information prior to the filing of a patent application.

9.           Intellectual Property

All rights in inventions, discoveries, biological material, or software created in the course of the Research shall be the property of NOTRE DAME. NOTRE DAME shall promptly report any such inventions, discoveries, biological material or software to SPONSOR upon receipt of a written report from the Principal Investigator.

a)           Patents

NOTRE DAME agrees to cause patent applications to be filed and prosecuted in its name at SPONSOR's request and expense on inventions or discoveries conceived and reduced to practice in the course of the Research (“Project IP”). NOTRE DAME shall promptly notify SPONSOR and provide it a copy of any such patent application. From the date of notification, SPONSOR shall have a six (6) month period to negotiate the terms of an exclusive license agreement for Project IP and NOTRE DAME agrees to negotiate these license terms and conditions consistent with the License Agreement in Attachment C, provided Sponsor is in compliance with this Agreement. During this period NOTRE DAME will not offer a commercial license for Project IP to any other party.

In the event SPONSOR does not agree, within thirty (30) days after notification of NOTRE DAME's intent to file a patent application, to support said filing, NOTRE DAME may file at its own expense and SPONSOR shall have no further rights in that patent application.

b)           Unpatented Technology

All rights in technology created in the performance of the Research for which NOTRE DAME does not seek patent protection shall be owned by NOTRE DAME. Upon receipt of a written description or sample of such technology, SPONSOR shall have a six (6) month period to negotiate the terms of an exclusive license agreement for Project IP and NOTRE DAME agrees to negotiate these license terms and conditions consistent with the License Agreement in Attachment C, provided Sponsor is in compliance with this Agreement. During this period NOTRE DAME will not offer a commercial license for Project IP to any other party.

  

  

  

	
  

	
c)

	
Grant of Rights

For disclosures for which the SPONSOR provides notice to NOTRE DAME under §9a., NOTRE DAME grants the SPONSOR a non-exclusive, paid-up, royalty-free license for internal use on any Joint Intellectual Property developed pursuant to this agreement.  SPONSOR will bear the cost of preparing, filing, prosecuting and maintenance of the patent(s) as outlined in § 9a.

	
  

	
d)

	
Background Intellectual Property

“Background Intellectual Property” shall mean NOTRE DAME Patents with the following patent number:

# 6,218,185, issued April 17, 2001, entitled “Piggybac transposon-based genetic transformation system for insects”, # 6,551,825, issued April 22, 2003 entitled “Piggybac transposon-based genetic transformation system for insects”,

# 6,962,810, issued November 8, 2005 entitled “Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac”, # 7,105,343, issued September 12, 2006 entitled “Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac”, and Application # 11/454.947 filed June 19, 2006 entitled “Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector Piggybac”.

Sponsor has certain rights to Background Intellectual Property. From the date of notification pursuant to 9.a), SPONSOR shall have a six (6) month period to negotiate the terms of a license agreement for Project IP and Background IP and NOTRE DAME agrees to negotiate these license terms and conditions consistent with the License Agreement in Attachment C, provided Sponsor is in compliance with this Agreement.

 

10.           Collaboration

It is understood that the NOTRE DAME investigators shall be free to discuss the Research with other investigators and to collaborate with them to the extent that no rights under any other agreement between the parties are infringed. .

11.           Indemnification

SPONSOR hereby waives, and agrees to indemnify, defend, and hold harmless NOTRE DAME and its employees, agents, and students from any claim, loss, cost, expense, or liability of any kind including reasonable attorney's fees and expenses arising out of or connected with this Agreement or the Research, except to the extent such claim is due to the negligence of NOTRE DAME, and including, without limitation, product liability claims relating to products based on the Research. NOTRE DAME shall promptly notify SPONSOR of any such claim and shall cooperate with SPONSOR and its insurance carrier in the defense of the claim. SPONSOR agrees to consult with NOTRE DAME regarding the defense of such claim and to submit any proposed settlement to NOTRE DAME in advance of its approval.

  

  

  

12.           Warranties

NOTRE DAME MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO ANY MATTER WHATSOEVER, INCLUDING, WITHOUT LIMITATION, THE CONDITION, ORIGINALITY, OR ACCURACY OF THE RESEARCH OR ANY INVENTION(S) OR PRODUCT(S), WHETHER TANGIBLE OR INTANGIBLE, CONCEIVED, DISCOVERED, OR DEVELOPED UNDER THIS AGREEMENT; OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE RESEARCH OR ANY SUCH INVENTION OR PRODUCT. NOTRE DAME SHALL NOT BE LIABLE FOR ANY DIRECT, CONSEQUENTIAL, OR OTHER DAMAGES SUFFERED BY SPONSOR, ANY LICENSEE, OR ANY OTHERS RESULTING FROM THE USE OF THE RESEARCH OR ANY SUCH INVENTION OR PRODUCT.

13.           Independent Contractor

For the purposes of this Agreement and all services to be provided hereunder, each party shall be, and shall be deemed to be, an independent contractor and not an agent or employee of the other party. Neither party shall have authority to make any statements, representations nor commitments of any kind, or to take any action, which shall be binding on the other party, except as may be explicitly provided for herein or authorized by the other party in writing.

14.           Governing Law

The validity and interpretation of this Agreement shall be governed by the laws of the State of Indiana in the United States of America.

15.           Assignment

This Agreement shall not be assignable by either party without the prior written consent of the other party.  Such consent will not be unreasonably withheld.  Any and all assignments not made in accordance with this section shall be void.

16.           Notices

Any notice or report required or permitted to be given under this Agreement shall be deemed to have been sufficiently given for all purposes if mailed by first class certified or registered mail to the following addresses of either party:

Director, Research Contracts & Awards

University of Notre Dame

940 Grace Hall

Notre Dame, Indiana  46556

and

Kim Thompson, CEO

Kraig Biocraft Laboratories

120 North Washington Square, Suite 805

Lansing, MI  48933

or to such other addresses as shall hereafter have been furnished by written notice to the other party.

 

  

  

  

 

17.           Title to Equipment

NOTRE DAME shall retain title to all equipment purchased and/or fabricated by it with funds provided by SPONSOR under this Agreement.

18.           No Oral Modification

No change, modification, extension, termination, or waiver of this Agreement, or any of the provisions herein contained, shall be valid unless made in writing and signed by duly authorized representatives of the parties hereto.

19.           Term and Termination

This Agreement shall expire on March 31, 2016 unless extended or sooner terminated in accordance with the provisions of this section.

Either party may terminate this Agreement by giving the other party ninety (90) days prior written notice of its election to terminate. In addition, NOTRE DAME may terminate this Agreement immediately if circumstances beyond its control preclude continuation of the Research.

Upon termination of this Agreement, SPONSOR shall reimburse NOTRE DAME for all reasonable expenses or uncancellable commitments incurred as of the date of notice of termination but not to exceed the total amount committed under this Agreement.

Termination or expiration of this Agreement for reasons other than an unremedied failure to meet the material obligations under this Agreement shall not affect the rights and obligations of the parties accrued prior to termination.

20.           Entire Agreement

This instrument contains the entire Agreement between parties hereto. No verbal agreement, conversation or representation between any officers, agents, or employees of the parties hereto either before or after the execution of this Agreement, shall affect or modify any of the terms or obligations herein contained.

IN Witness WHEREOF, the parties have caused this Agreement to be executed as of

 

 

	 
Kraig Biocraft Laboratories, Inc.

 

By: _/s/ Kim Thompson________________

Kim Thompson

Chief Executive Officer

Date: ___2/23/2015___________________

	 
The University of Notre Dame du Lac

 

By: _/s/ Greg Luttrell________________

Greg Luttrell

Director, Research Contracts & Awards

Date: __3/4/2015___________________Exhibit 10.53

 

REVEN HOUSING
REIT, INC.

 

RESTRICTED
STOCK AGREEMENT

 

FOR

 

Chad M. Carpenter

 

1.                 
Award of Restricted Stock. The Committee hereby grants, as of October 16, 2014 (the “Date
of Grant”), to Chad M. Carpenter, 5,500,000 restricted shares of the Company’s Common Stock, par value $0.001
per share (collectively the "Restricted Stock"). The Restricted Stock shall be subject to the terms, provisions
and restrictions set forth in this Agreement and the Company’s Amended and Restated 2012 Incentive Compensation Plan (the
“Plan”), which is incorporated herein for all purposes. As a condition to entering into this Agreement, and as a condition
to the issuance of any Shares (or any other securities of the Company), the Recipient agrees to be bound by all of the terms and
conditions herein and in the Plan. Unless otherwise provided herein, terms used herein that are defined in the Plan and not defined
herein shall have the meanings attributable thereto in the Plan.

 

2.                 
Vesting of Restricted Stock.

 

(a)               
General Vesting. The shares of Restricted Stock shall become vested in the following amounts, at the
following times and upon the following conditions, provided that the Continuous Service of the Recipient continues through and
on the applicable Vesting Date:

 

	Number of Shares of Restricted Stock	Vesting Date
	 	 
	1,375,000	The date upon which the Company consummates an equity raise of at least $25 million (or any lesser amount if the equity raise is a registered public offering).
	 	 
	1,650,000	After the first Vesting Date, the earlier to occur of:  (i) the date the Company raises an additional $50 million in an equity financing or a series of equity financings; or (ii) the date the Company consummates portfolio acquisition(s) of an aggregate amount of $100 million commencing August 1, 2014. 

 

    	 

    	 

    

 

	Number of Shares of Restricted Stock	Vesting Date
	 	 
	1,925,000	After the second Vesting Date, the earlier to occur of:  (i) the date the Company raises an additional $150 million in an equity financing or a series of equity financings; or (ii) the date the Company consummates additional portfolio acquisition(s) of an aggregate amount of $300 million.
	 	 
	550,000	The date upon which the Company makes cash distributions to stockholders at a rate of at least $0.01 per share annualized over any four (4) consecutive fiscal quarters.

 

For vesting conditions
relating to equity raises, any investment either directly by Allied Fortune, entities under management of Allied Fortune, or investors
introduced to or otherwise referred to the Company by Allied Fortune (including Xiaofan Bai and his associates) (collectively,
the “Allied Investors”) shall not be counted towards the dollar thresholds; provided, however, unless such Allied Investors’
investments are in a public offering.

 

Except as otherwise
provided in Sections 2(b), 2(c), 2(d), and 4 hereof, there shall be no proportionate or partial vesting of shares of Restricted
Stock in or during the months, days or periods prior to each Vesting Date, and all vesting of shares of Restricted Stock shall
occur only on the applicable Vesting Date.

 

(b)              
Acceleration of Vesting Upon Change in Control. In the event that a Change in Control of the Company
occurs during the Recipient's Continuous Service, the shares of Restricted Stock subject to this Agreement shall become immediately
vested as of the date of the Change in Control.

 

(c)               
Acceleration of Vesting at Company Discretion. Notwithstanding any other term or provision of this
Agreement, the Board or the Committee shall be authorized, in its sole discretion, based upon its review and evaluation of the
performance of the Recipient and of the Company, to accelerate the vesting of any shares of Restricted Stock under this Agreement,
at such times and upon such terms and conditions as the Board or the Committee shall deem advisable.

 

(d)              
Definitions. For purposes of this Agreement, the following terms shall have the meanings indicated:

 

    	2

    	 

    

 

(i)                
“Change in Control” means the occurrence of any of the following:

 

(A)            
The acquisition by any Person of Beneficial Ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act)
of more than fifty percent (50%) of either (A) the then outstanding shares of common stock of the Company (the “Outstanding
Company Common Stock”) or (B) the combined voting power of the then outstanding voting securities of the Company entitled
to vote generally in the election of directors (the “Outstanding Company Voting Securities) (the foregoing Beneficial Ownership
hereinafter being referred to as a "Controlling Interest"); provided, however, that for purposes of this Section 2(d)(i),
the following acquisitions shall not constitute or result in a Change of Control: (1) any acquisition directly from the Company;
(2) any acquisition by the Company; (3) any acquisition by any Person that as of the Date of Grant owns Beneficial Ownership of
a Controlling Interest; (4) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the
Company; or (5) any acquisition by any corporation pursuant to a transaction which complies with clauses (1), (2) and (3) of subsection
(C) below; or

 

(B)             
During any period of two (2) consecutive years (not including any period prior to the Date of Grant) individuals who constitute
the Board on the Date of Grant (the “Incumbent Board”) cease for any reason to constitute at least a majority of the
Board; provided, however, that any individual becoming a director subsequent to the Date of Grant whose election, or nomination
for election by the Company’s shareholders, was approved by a vote of at least a majority of the directors then comprising
the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this
purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest
with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on
behalf of a Person other than the Board; or

 

(C)             
Consummation of a reorganization, merger, statutory share exchange or consolidation or similar corporate transaction involving
the Company, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets
or stock of another entity by the Company (each a “Business Combination”), in each case, unless, following such Business
Combination, (1) all or substantially all of the individuals and entities who were the Beneficial Owners, respectively, of the
Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination beneficially
own, directly or indirectly, more than fifty percent (50%) of the then outstanding shares of common stock and the combined voting
power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of
the corporation resulting from such Business Combination (including, without limitation, a corporation which as a result of such
transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries)
in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company
Common Stock and Outstanding Company Voting Securities, as the case may be, (2) no Person (excluding any employee benefit plan
(or related trust) of the Company or such corporation resulting from such Business Combination or any Person that as of the Date
of Grant owns Beneficial Ownership of a Controlling Interest) beneficially owns, directly or indirectly, fifty percent (50%) or
more of the then outstanding shares of common stock of the corporation resulting from such Business Combination or the combined
voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior
to the Business Combination and (3) at least a majority of the members of the Board of Directors of the corporation resulting from
such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the
action of the Board, providing for such Business Combination; or

 

    	3

    	 

    

 

(D)            
Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company.

 

(ii)              
“Consultant” means any person (other than an Employee or a Director, solely with respect to rendering
services in such person’s capacity as a Director) who is engaged by the Company to render consulting or advisory services
to the Company.

 

(iii)            
“Continuous Service” means the continuous service to the Company, without interruption or termination,
in any capacity of Employee, Director or Consultant. Continuous Service shall not be considered interrupted in the case of (A)
any approved leave of absence, (B) transfers among the Company, or any successor, in any capacity of Employee, Director or Consultant,
or (C) any change in status as long as the individual remains in the service of the Company in any capacity of Employee, Director
or Consultant. An approved leave of absence shall include sick leave, disability leave, military leave, or any other authorized
personal leave.

 

(iv)            
“Director” means a member of the Board.

 

(v)              
“Employee” means any person, including an Officer or Director, who is an employee of the Company.
The payment of a Director’s normal compensation and fee (as applicable to all Directors or Committee members, as the case
may be) by the Company shall not be sufficient to constitute “employment” by the Company.

 

(vi)            
“Non-Vested Shares” means any portion of the Restricted Stock subject to this Agreement that has
not become vested pursuant to this Section 2.

 

(vii)          
“Person” shall have the meaning ascribed to such term in Section 3(a)(9) of the Securities
Exchange Act of 1934 and used in Sections 13(d) and 14(d) thereof, and shall include a “group” as defined in Section
13(d) thereof.

 

(viii)        
“Vested Shares” means any portion of the Restricted Stock subject to this Agreement that is and
has become vested pursuant to this Section 2.

 

3.                 
Delivery of Restricted Stock. 

 

(a)               
Issuance of Stock Certificates and Legends. One or more stock certificates evidencing the Restricted
Stock shall be issued in the name of the Recipient but shall be held and retained by the Records Administrator of the Company
until the date (the “Applicable Date”) on which the shares (or a portion thereof) subject to this Restricted
Stock award become Vested Shares pursuant to Section 2 hereof, subject to the provisions of Section 4 hereof. All such stock certificates
shall bear the following legends, along with such other legends that the Board or the Committee shall deem necessary and appropriate
or which are otherwise required or indicated pursuant to any applicable stockholders agreement:

 

    	4

    	 

    

 

THE SHARES REPRESENTED BY THIS
CERTIFICATE ARE SUBJECT TO SUBSTANTIAL VESTING AND OTHER RESTRICTIONS AS SET FORTH IN THE RESTRICTED STOCK AGREEMENT BETWEEN THE
ISSUER AND THE ORIGINAL HOLDER OF THE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH RESTRICTIONS
ARE BINDING ON TRANSFEREES OF THESE SHARES, AND INCLUDE VESTING CONDITIONS WHICH MAY RESULT IN THE COMPLETE FORFEITURE OF THE SHARES.

 

(b)              
Stock Powers. The Recipient shall deposit with the Company stock powers or other instruments of transfer
or assignment, duly endorsed in blank with signature(s) guaranteed, corresponding to each certificate representing shares of Restricted
Stock until such shares become Vested Shares. If the Recipient shall fail to provide the Company with any such stock power or
other instrument of transfer or assignment, the Recipient hereby irrevocably appoints the Secretary of the Company as his attorney-in-fact,
with full power of appointment and substitution, to execute and deliver any such power or other instrument which may be necessary
to effectuate the transfer of the Restricted Stock (or assignment of distributions thereon) on the books and records of the Company.

 

(c)               
Delivery of Stock Certificates. On or after each Applicable Date, upon written request to the Company
by the Recipient, the Company shall promptly cause a new certificate or certificates to be issued for and with respect to all
shares that become Vested Shares on that Applicable Date, which certificate(s) shall be delivered to the Recipient as soon as
administratively practicable after the date of receipt by the Company of the Recipient's written request. The new certificate
or certificates shall continue to bear those legends and endorsements that the Company shall deem necessary or appropriate (including
those relating to restrictions on transferability and/or obligations and restrictions under the Securities Laws).

 

(d)              
Issuance Without Certificates. If the Company is authorized
to issue Shares without certificates, then the Company may, in the discretion of the Committee, issue Shares pursuant to this Agreement
without certificates, in which case any references in this Agreement to certificates shall instead refer to whatever evidence may
be issued to reflect the Recipient’s ownership of the Shares subject to the terms and conditions of this Agreement.

 

4.                 
Forfeiture of Non-Vested Shares. If the Recipient’s Continuous Service with the Company is terminated
for any reason, any Shares of Restricted Stock that are not Vested Shares, and that do not become Vested Shares pursuant to Section
2 hereof as a result of such termination, shall be forfeited immediately upon such termination of Continuous Service and revert
back to the Company without any payment to the Recipient. The Committee shall have the power and authority to enforce on behalf
of the Company any rights of the Company under this Agreement in the event of the Recipient’s forfeiture of Non-Vested Shares
pursuant to this Section 4.

 

    	5

    	 

    

 

5.                 
Rights with Respect to Restricted Stock.

 

(a)               
General. Except as otherwise provided in this Agreement, the Recipient shall have, with respect to
all of the shares of Restricted Stock, whether Vested Shares or Non-Vested Shares, all of the rights of a holder of shares of
common stock of the Company, including without limitation (i) the right to vote such Restricted Stock, (ii) the right to receive
dividends, if any, as may be declared on the Restricted Stock from time to time, and (iii) the rights available to all holders
of shares of common stock of the Company upon any merger, consolidation, reorganization, liquidation or dissolution, stock split-up,
stock dividend or recapitalization undertaken by the Company; provided, however, that all of such rights shall be subject to the
terms, provisions, conditions and restrictions set forth in this Agreement (including without limitation conditions under which
all such rights shall be forfeited). Any Shares issued to the Recipient as a dividend with respect to shares of Restricted Stock
shall have the same status and bear the same legend as the shares of Restricted Stock and shall be held by the Company, if the
shares of Restricted Stock that such dividend is attributed to is being so held, unless otherwise determined by the Committee.

 

(b)              
Adjustments to Shares. If at any time while this Agreement is in effect (or Shares granted hereunder
shall be or remain unvested while Recipient’s Continuous Service continues and has not yet terminated or ceased for any
reason), there shall be any increase or decrease in the number of issued and outstanding Shares of the Company through the declaration
of a stock dividend or through any recapitalization resulting in a stock split-up, combination or exchange of such Shares, then
and in that event, the Board or the Committee shall make any adjustments it deems fair and appropriate, in view of such change,
in the number of shares of Restricted Stock then subject to this Agreement in order to equitably provide that the Recipient’s
economic situation is the same as prior to the change. If any such adjustment shall result in a fractional Share, such fraction
shall be disregarded.

 

(c)               
No Restrictions on Certain Transactions. Notwithstanding any term or provision of this Agreement to
the contrary, the existence of this Agreement, or of any outstanding Restricted Stock awarded hereunder, shall not affect in any
manner the right, power or authority of the Company to make, authorize or consummate: (i) any or all adjustments, recapitalizations,
reorganizations or other changes in the Company's capital structure or its business; (ii) any merger, consolidation or similar
transaction by or of the Company; (iii) any offer, issue or sale by the Company of any capital stock of the Company, including
any equity or debt securities, or preferred or preference stock that would rank prior to or on parity with the Restricted Stock
and/or that would include, have or possess other rights, benefits and/or preferences superior to those that the Restricted Stock
includes, has or possesses, or any warrants, options or rights with respect to any of the foregoing; (iv) the dissolution or liquidation
of the Company; (v) any sale, transfer or assignment of all or any part of the stock, assets or business of the Company;
or (vi) any other corporate transaction, act or proceeding (whether of a similar character or otherwise).

 

    	6

    	 

    

 

6.                 
Transferability. Unless otherwise determined by the Committee, the shares of Restricted Stock are
not transferable unless and until they become Vested Shares in accordance with this Agreement, otherwise than by will or under
the applicable laws of descent and distribution. The terms of this Agreement shall be binding upon the executors, administrators,
heirs, successors and assigns of the Recipient. Except as otherwise permitted pursuant to the first sentence of this Section,
any attempt to effect a Transfer of any shares of Restricted Stock prior to the date on which the shares become Vested Shares
shall be void ab initio. For purposes of this Agreement, “Transfer” shall mean any sale, transfer, encumbrance,
gift, donation, assignment, pledge, hypothecation, or other disposition, whether similar or dissimilar to those previously enumerated,
whether voluntary or involuntary, and including, but not limited to, any disposition by operation of law, by court order, by judicial
process, or by foreclosure, levy or attachment.

 

7.                 
Tax Matters; Section 83(b) Election.

 

(a)               
Section 83(b) Election. If the Recipient properly elects, within thirty (30) days of the Date of Grant,
to include in gross income for federal income tax purposes an amount equal to the fair market value (as of the Date of Grant)
of the Restricted Stock pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended (the “Code”),
the Recipient shall make arrangements satisfactory to the Company to pay to the Company any federal, state or local income taxes
required to be withheld with respect to the Restricted Stock. If the Recipient shall fail to make such tax payments as are required,
the Company shall, to the extent permitted by law, have the right to deduct from any payment of any kind (including without limitation,
the withholding of any Shares that otherwise would be issued to the Recipient under this Agreement) otherwise due to the Recipient
any federal, state or local taxes of any kind required by law to be withheld with respect to the Restricted Stock.

 

(b)              
No Section 83(b) Election. If the Recipient does not properly make the election described in paragraph
7(a) above, the Recipient shall, no later than the date or dates as of which the restrictions referred to in this Agreement hereof
shall lapse, pay to the Company, or make arrangements satisfactory to the Committee for payment of, any federal, state or local
taxes of any kind required by law to be withheld with respect to the Restricted Stock (including without limitation the vesting
thereof), and the Company shall, to the extent permitted by law, have the right to deduct from any payment of any kind (including
without limitation, the withholding of any Shares that otherwise would be distributed to the Recipient under this Agreement) otherwise
due to Recipient any federal, state, or local taxes of any kind required by law to be withheld with respect to the Restricted
Stock.

 

(c)               
Satisfaction of Withholding Requirements. The Recipient may satisfy the withholding requirements with
respect to the Restricted Stock pursuant to any one or combination of the following methods:

 

(i)                
payment in cash; or

 

(ii)              
if and to the extent permitted by the Committee, payment by surrendering unrestricted previously held Shares which have
a value equal to the required withholding amount or the withholding of Shares that otherwise would be deliverable to the Recipient
pursuant to this Award. The Recipient may surrender Shares either by attestation or by delivery of a certificate or certificates
for shares duly endorsed for transfer to the Company, and if required with medallion level signature guarantee by a member firm
of a national stock exchange, by a national or state bank (or guaranteed or notarized in such other manner as the Committee may
require).

 

    	7

    	 

    

 

(d)              
Recipient’s Responsibilities for Tax Consequences. Tax consequences on the Recipient (including
without limitation federal, state, local and foreign income tax consequences) with respect to the Restricted Stock (including
without limitation the grant, vesting and/or forfeiture thereof) are the sole responsibility of the Recipient. The Recipient shall
consult with his or her own personal accountant(s) and/or tax advisor(s) regarding these matters, the making of a Section 83(b)
election, and the Recipient’s filing, withholding and payment (or tax liability) obligations.

 

8.                 
Amendment, Modification & Assignment; Non-Transferability.  This Agreement may only be modified
or amended in a writing signed by the parties hereto. No promises, assurances, commitments, agreements, undertakings or representations,
whether oral, written, electronic or otherwise, and whether express or implied, with respect to the subject matter hereof, have
been made by either party which are not set forth expressly in this Agreement. Unless otherwise consented to in writing by the
Company, in its sole discretion, this Agreement (and Recipient’s rights hereunder) may not be assigned, and the obligations
of Recipient hereunder may not be delegated, in whole or in part. The rights and obligations created hereunder shall be binding
on the Recipient and his heirs and legal representatives and on the successors and assigns of the Company.

 

9.                 
Complete Agreement. This Agreement (together with those agreements and documents expressly referred
to herein, for the purposes referred to herein) embody the complete and entire agreement and understanding between the parties
with respect to the subject matter hereof, and supersede any and all prior promises, assurances, commitments, agreements, undertakings
or representations, whether oral, written, electronic or otherwise, and whether express or implied, which may relate to the subject
matter hereof in any way.

 

10.             
Miscellaneous.

 

(a)               
No Right to (Continued) Employment or Service. This Agreement and the grant of Restricted Stock hereunder
shall not confer, or be construed to confer, upon the Recipient any right to employment or service, or continued employment or
service, with the Company.

 

(b)              
No Limit on Other Compensation Arrangements. Nothing contained in this Agreement shall preclude the
Company from adopting or continuing in effect other or additional compensation plans, agreements or arrangements, and any such
plans, agreements and arrangements may be either generally applicable or applicable only in specific cases or to specific persons.

 

(c)               
Severability. If any term or provision of this Agreement is or becomes or is deemed to be invalid,
illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed
or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially
altering the purpose or intent of this Agreement and the grant of Restricted Stock hereunder, such provision shall be stricken
as to such jurisdiction and the remainder of this Agreement and the award hereunder shall remain in full force and effect).

 

    	8

    	 

    

 

(d)              
No Trust or Fund Created. Neither this Agreement nor the grant of Restricted Stock hereunder shall
create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and the
Recipient or any other person. To the extent that the Recipient or any other person acquires a right to receive payments from
the Company pursuant to this Agreement, such right shall be no greater than the right of any unsecured general creditor of the
Company.

 

(e)               
Law Governing. This Agreement shall be governed by and construed and enforced in accordance with the
internal laws of the State of California (without reference to the conflict of laws rules or principles thereof).

 

(f)               
Interpretation. The Recipient accepts the Restricted Stock subject to all of the terms, provisions
and restrictions of this Agreement and the Plan. The undersigned Recipient hereby accepts as binding, conclusive and final all
decisions or interpretations of the Board or the Committee upon any questions arising under this Agreement or the Plan.

 

(g)              
Headings. Section, paragraph and other headings and captions are provided solely as a convenience
to facilitate reference. Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning
or interpretation of this Agreement or any term or provision hereof.

 

(h)              
Notices. Any notice under this Agreement shall be in writing and shall be deemed to have been duly
given when delivered personally or when deposited in the United States mail, registered, postage prepaid, and addressed, in the
case of the Company, to the Company’s President at 7911 Herschel Avenue, Suite 201, La Jolla, California 92037, or if the
Company should move its principal office, to such principal office, and, in the case of the Recipient, to the Recipient’s
last permanent address as shown on the Company’s records, subject to the right of either party to designate some other address
at any time hereafter in a notice satisfying the requirements of this Section.

 

(i)                
Section 409A.

 

(a)It is intended
that the Restricted Stock awarded pursuant to this Agreement be exempt from Section 409A of the Code (“Section 409A”)
because it is believed that the Agreement does not provide for a deferral of compensation and accordingly that the Agreement does
not constitute a nonqualified deferred compensation plan within the meaning of Section 409A. The provisions of this Agreement shall
be interpreted in a manner consistent with this intention, and the provisions of this Agreement may not be amended, adjusted, assumed
or substituted for, converted or otherwise modified without the Recipient’s prior written consent if and to the extent that
the Company believes or reasonably should believe that such amendment, adjustment, assumption or substitution, conversion or modification
would cause the award to violate the requirements of Section 409A.

 

    	9

    	 

    

 

(b)In the event
that either the Company or the Recipient believes, at any time, that any benefit or right under this Agreement is subject to Section
409A, and does not comply with the requirements of Section 409A, it shall promptly advise the other and the Company and the Recipient
shall negotiate reasonably and in good faith to amend the terms of such benefits and rights, if such an amendment may be made in
a commercially reasonable manner, such that they comply with Section 409A with the most limited possible economic affect on the
Recipient and on the Company.

 

(c)Notwithstanding
the foregoing, the Company does not make any representation to the Recipient that the shares of Restricted Stock awarded pursuant
to this Agreement are exempt from, or satisfies, the requirements of Section 409A, and the Company shall have no liability or other
obligation to indemnify or hold harmless the Recipient or any Beneficiary for any tax, additional tax, interest or penalties that
the Recipient or any Beneficiary may incur in the event that any provision of this Agreement, or any amendment or modification
thereof or any other action taken with respect thereto that either is consented to by the Recipient or that the Company reasonably
believes should not result in a violation of Section 409A, is deemed to violate any of the requirements of Section 409A.

 

(j)                
Non-Waiver of Breach. The waiver by any party hereto of the other party's prompt and complete performance,
or breach or violation, of any term or provision of this Agreement shall be effected solely in a writing signed by such party,
and shall not operate nor be construed as a waiver of any subsequent breach or violation, and the waiver by any party hereto to
exercise any right or remedy which he or it may possess shall not operate nor be construed as the waiver of such right or remedy
by such party, or as a bar to the exercise of such right or remedy by such party, upon the occurrence of any subsequent breach
or violation.

 

(k)              
Counterparts. This Agreement may be executed in two or more separate counterparts, each of which shall
be an original, and all of which together shall constitute one and the same agreement.

 

    	10

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto, intending to be legally bound, have executed this Agreement as of the date first written above.

 

	 	REVEN HOUSING REIT, INC.
	 	 	 
	 	By:  	/s/ Thad L. Meyer
	 	 	Thad L. Meyer
	 	 	Chief Financial Officer

 

Agreed and Accepted:

 

RECIPIENT:

 

	By:  	/s/ Chad M. Carpenter	 
	 	Chad M. Carpenter	 

 

    	11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]